PRTA News and Press, Prothena Corporation plc

2024-07-03 23:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-07-02 13:00:00 ET Summary 21 new analysts joined in June and are highlighted today. Each is introduced with some details on their first investment thesis on Seeking Alpha and their background. Analysts cover a range of sectors including biotech, technology, consumer staples, ...

2024-06-07 14:15:17 ET Summary Prothena Corporation is a late-stage biotech which specializes in proteinopathies and neurodegenerative diseases. They have a diverse pipeline. However, their main assets in attention currently are a first-in-class amyloid depleter, Birtamimab (wholl...

2024-06-02 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-28 16:23:34 ET More on Prothena Seeking Alpha’s Quant Rating on Prothena Historical earnings data for Prothena Financial information for Prothena Read the full article on Seeking Alpha For further details see: Bristol Myers licenses...

Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate a Phase 1 clinical trial for PRX019 in 2024 Prothena Corporation plc (NASDAQ:PRTA),...

2024-05-23 11:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-12 11:00:00 ET More on Acadia Pharma, BridgeBio Pharma, etc. ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript ACADIA Pharmaceuticals Inc. 2024 Q1 - Results - Earnings Call Presentation Rocket Pharmaceuticals: Cautiously Optimistic (Rating U...

2024-05-08 17:00:06 ET More on Prothena Prothena: Alzheimer's Data Update In 2024 Could Move The Needle Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript Prothena Corporation plc 2023 Q4 - Results - Earnings Call Presentation Prothena appoints ...

Net cash used in operating and investing activities was $73.2 million in the first quarter of 2024; quarter-end cash and restricted cash position was $548.7 million Advanced potential best-in-class Alzheimer’s disease portfolio: initial data supportive of ongoing Phase 1 clinical trial...